OCUL - Ocular Therapeutix Inc Stock Price, Fair Value and News

$10.80-0.50 (-4.42%)

Delayed as of 23 Oct 2024, 03:04 pm ET

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

OCUL Price Action

Last 7 days

10.5%

Last 30 days

25.8%

Last 90 days

42.9%

Trailing 12 Months

387.1%

OCUL RSI Chart

OCUL Valuation

Market Cap

1.8B

Price/Earnings (Trailing)

-12.73

Price/Sales (Trailing)

28.84

Price/Free Cashflow

-19.45

OCUL Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

OCUL Fundamentals

OCUL Revenue

Revenue (TTM)

61.1M

Rev. Growth (Yr)

8.26%

Rev. Growth (Qtr)

11.28%

OCUL Earnings

Earnings (TTM)

-138.4M

Earnings Growth (Yr)

-111.67%

Earnings Growth (Qtr)

32.49%

OCUL Profitability

Return on Equity

-36.63%

Return on Assets

-26.76%

Free Cashflow Yield

-5.14%

OCUL Investor Care

Shares Dilution (1Y)

96.41%

Diluted EPS (TTM)

-1.18

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	59.8M	61.1M	0	0
2023	51.7M	54.6M	57.7M	58.4M
2022	49.4M	49.9M	49.7M	51.5M
2021	22.1M	32.3M	38.6M	43.5M
2020	6.3M	7.3M	12.3M	17.4M
2019	2.1M	2.1M	2.5M	4.2M
2018	1.8M	2.0M	2.0M	2.0M
2017	1.9M	1.9M	1.9M	1.9M
2016	1.8M	1.8M	1.8M	1.9M
2015	1.2M	1.5M	1.8M	1.8M
2014	200.5K	391.0K	581.5K	772.0K
2012	0	0	0	10.0K

Get all data in R, Python etc through our Historical Stock Data APIs

About Ocular Therapeutix Inc

Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets ReSure Sealant, an ophthalmic device to prevent wound leaks in corneal incisions following cataract surgery; and DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing OTX-TKI, an axitinib intravitreal implant that is in phase 1 clinical trials for the treatment of wet age-related macular degeneration and other retinal diseases; OTX-TIC, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. Ocular Therapeutix, Inc. has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the Company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC, as well as a discovery collaboration with Mosaic Biosciences to identify new targets and therapeutic agents for the treatment of dry age-related macular degeneration (dMAD). The company was incorporated in 2006 and is headquartered in Bedford, Massachusetts.

CEO	Mr. Antony Mattessich
WEBSITE	ocutx.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	274

Ocular Therapeutix Inc Frequently Asked Questions

What is the ticker symbol for Ocular Therapeutix Inc? What does OCUL stand for in stocks?

OCUL is the stock ticker symbol of Ocular Therapeutix Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Ocular Therapeutix Inc (OCUL)?

As of Tue Oct 22 2024, market cap of Ocular Therapeutix Inc is 1.76 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of OCUL stock?

You can check OCUL's fair value in chart for subscribers.

Is Ocular Therapeutix Inc a good stock to buy?

The fair value guage provides a quick view whether OCUL is over valued or under valued. Whether Ocular Therapeutix Inc is cheap or expensive depends on the assumptions which impact Ocular Therapeutix Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for OCUL.

What is Ocular Therapeutix Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Tue Oct 22 2024, OCUL's PE ratio (Price to Earnings) is -12.73 and Price to Sales (PS) ratio is 28.84. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. OCUL PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Ocular Therapeutix Inc's stock?

In the past 10 years, Ocular Therapeutix Inc has provided -0.017 (multiply by 100 for percentage) rate of return.